Replies to post #22973 on Biotech Values

[gfp927z]

Dew, As I see it, Cortex's hiring of a CSO/COO at this time indicates that 1) Stoll is confident that he'll get the CX-717 BP deal fairly soon, and 2) that he's most likely planning to do an inlicense of a late stage program (he discussed this possibility favorably and at length at the December shareholder's meeting presentation). They gave the new CSO a huge grant of 750,000 options, which I found surprising.

I'm tempted to try to get up to speed on your ADH pick, since it does still look cheap, in spite of its recent run. GTCB still scares me, but the recent EMEA/CHMP tea leaves sound promising.

BTW, just wondering if you or others here have an opinion on Discovery Labs? I recently took a medium sized position. They have an FDA approval decision coming up in several months (Surfaxin), and the company still appears to be somewhat under the radar. Any input from the board is appreciated.